Psoriasis is a common inflammatory skin disease linked to several long-term health conditions, such as heart disease, ...

Between 20 and 30 percent of people with psoriasis eventually develop a second, more disabling problem: painful joint ...

Researchers from the Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC) ...

The National Psoriasis Foundation issued a new position statement that clarifies the definition of psoriasis disease severity. The new criteria define psoriasis severity as “mild” or “moderate to ...

Apremilast for 32 weeks significantly improves the signs and symptoms of moderate to severe genital psoriasis with a consistent safety profile.

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, this condition known as psoriatic arthritis can lead to ...

In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

Incorporating patient-reported outcome measures, such as quality of life, as well as looking into real-world data, is ...

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

Topical or oral corticosteroids generally cost $10 to $20 a month.

SAN FRANCISCO, CA, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) is ...

Risankizumab improved visible psoriasis and reduced subclinical vascular inflammation on optical coherence tomography over 52 ...